An observational study in Chronic Kidney Diseases, sponsored by Hoffmann-La Roche. Completed at 7 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-24.
Sponsored by Hoffmann-La Roche · Observational
This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis participant population in Israel. Participating physicians will be requested to interview eligible participants with CKD not on dialysis and to complete for them a satisfaction survey for anemia treatment. The survey will be completed twice, once at study start and once at six months' follow-up.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 196 is close to the median of 192 across 1,033 observational studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult participants with CKD not on-dialysis treated with ESAs
Exclusion Criteria:
Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
Drug: ESA · Other: Satisfaction Survey Questionnaire
Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
Percentage of Participants by ESA Types at Baseline
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Time frame: Baseline
Percentage of Participants by ESA Types at Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Time frame: Month 6
Percentage of Participants by Frequency of ESA Use at Baseline
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Time frame: Baseline
Percentage of Participants by Frequency of ESA Use at Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Time frame: Month 6
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
Time frame: Baseline
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
Time frame: Month 6
Percentage of Participants by Different CKD Stages
Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Different Injection Administration Modes
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported.
Time frame: Baseline, Month 6
Percentage of Participants With Interest in Learning to Inject Independently
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Need for Improvement in Treatment Frequency
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Preferred Treatment Frequency
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Convenience of Syringe Usage
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Injection Site Pain
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported.
Time frame: Baseline, Month 6
Percentage of Participants by Injection Site Pain by ESA Type
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported.
Time frame: Baseline, Month 6
| Milestone | Chronic Renal Anemia Participants |
|---|---|
| Started | 196 |
| Completed | 151 |
| Not completed | 45 |
| Withdrew: Not completed survey at month 6 | 45 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera | 51.5 (44.3 to 58.7) |
| Recormon | 17.3 (12.3 to 23.4) |
| Eprex | 10.7 (6.8 to 15.9) |
| Aranesp | 20.4 (15.0 to 26.7) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera | 43.7 (35.7 to 52.0) |
| Recormon | 19.2 (13.3 to 26.4) |
| Eprex | 12.6 (7.7 to 19.0) |
| Aranesp | 24.5 (17.9 to 32.2) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Three times a week | 2.6 (0.8 to 5.9) |
| Twice a week | 7.2 (4.0 to 11.8) |
| Once a week | 14.9 (10.2 to 20.7) |
| Every 2 weeks | 26.2 (20.1 to 32.9) |
| Every 4 weeks | 38.5 (31.6 to 45.7) |
| Other | 10.8 (6.8 to 16.0) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Three times a week | 1.3 (0.2 to 4.7) |
| Twice a week | 4.0 (1.5 to 8.4) |
| Once a week | 15.9 (10.5 to 22.7) |
| Every 2 weeks | 25.2 (18.5 to 32.9) |
| Every 4 weeks | 39.1 (31.2 to 47.3) |
| Other | 14.6 (9.4 to 21.2) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera : Three times a week (n=100) | 2.0 |
| Mircera : Twice a week (n=100) | 4.0 |
| Mircera : Once a week (n=100) | 1.0 |
| Mircera : Every 2 weeks (n=100) | 26.0 |
| Mircera : Every 4 weeks (n=100) | 67.0 |
| Mircera : Other (n=100) | 0 |
| Recormon : Three times a week (n=34) | 0 |
| Recormon : Twice a week (n=34) | 17.6 |
| Recormon : Once a week (n=34) | 38.2 |
| Recormon : Every 2 weeks (n=34) | 17.6 |
| Recormon : Every 4 weeks (n=34) | 5.9 |
| Recormon : Other (n=34) | 20.6 |
| Eprex : Three times a week (n=21) | 9.5 |
| Eprex : Twice a week (n=21) | 9.5 |
| Eprex : Once a week (n=21) | 42.9 |
| Eprex : Every 2 weeks (n=21) | 9.5 |
| Eprex : Every 4 weeks (n=21) | 4.8 |
| Eprex : Other (n=21) | 23.8 |
| Aranesp : Three times a week (n=40) | 2.5 |
| Aranesp : Twice a week (n=40) | 5.0 |
| Aranesp : Once a week (n=40) | 15.0 |
| Aranesp : Every 2 weeks (n=40) | 42.5 |
| Aranesp : Every 4 weeks (n=40) | 12.5 |
| Aranesp : Other (n=40) | 22.5 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera : Three times a week (n=66) | 1.5 |
| Mircera : Twice a week (n=66) | 1.5 |
| Mircera : Once a week (n=66) | 0 |
| Mircera : Every 2 weeks (n=66) | 18.2 |
| Mircera : Every 4 weeks (n=66) | 71.2 |
| Mircera : Other (n=66) | 7.6 |
| Recormon : Three times a week (n=29) | 0 |
| Recormon : Twice a week (n=29) | 10.3 |
| Recormon : Once a week (n=29) | 27.6 |
| Recormon : Every 2 weeks (n=29) | 37.9 |
| Recormon : Every 4 weeks (n=29) | 6.9 |
| Recormon : Other (n=29) | 17.2 |
| Eprex : Three times a week (n=19) | 5.3 |
| Eprex : Twice a week (n=19) | 5.3 |
| Eprex : Once a week (n=19) | 47.4 |
| Eprex : Every 2 weeks (n=19) | 15.8 |
| Eprex : Every 4 weeks (n=19) | 5.3 |
| Eprex : Other (n=19) | 21.1 |
| Aranesp : Three times a week (n=37) | 0 |
| Aranesp : Twice a week (n=37) | 2.7 |
| Aranesp : Once a week (n=37) | 18.9 |
| Aranesp : Every 2 weeks (n=37) | 32.4 |
| Aranesp : Every 4 weeks (n=37) | 24.3 |
| Aranesp : Other (n=37) | 21.6 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Stage 1 : Baseline (n=196) | 2.0 |
| Stage 1 : Month 6 (n=151) | 1.3 |
| Stage 2 : Baseline (n=196) | 10.2 |
| Stage 2 : Month 6 (n=151) | 13.9 |
| Stage 3 : Baseline (n=196) | 37.8 |
| Stage 3 : Month 6 (n=151) | 41.7 |
| Stage 4 : Baseline (n=196) | 37.8 |
| Stage 4 : Month 6 (n=151) | 30.5 |
| Stage 5 : Baseline (n=196) | 12.2 |
| Stage 5 : Month 6 (n=151) | 12.6 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Independently : Baseline (n=196) | 18.4 |
| Independently : Month 6 (n=151) | 23.2 |
| By a family member : Baseline (n=196) | 16.8 |
| By a family member : Month 6 (n=151) | 17.9 |
| Nurse at home : Baseline (n=196) | 3.6 |
| Nurse at home : Month 6 (n=151) | 3.3 |
| Nurse at the clinic : Baseline (n=196) | 58.2 |
| Nurse at the clinic : Month 6 (n=151) | 52.3 |
| Other: Baseline (n=196) | 3.1 |
| Other : Month 6 (n=151) | 3.3 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Baseline (n=160) | 6.3 (3.0 to 11.2) |
| Month 6 (n=116) | 4.3 (1.4 to 9.8) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Score 1 : Baseline (n=196) | 94.9 (90.8 to 97.5) |
| Score 1 : Month 6 (n=151) | 96.0 (91.6 to 98.5) |
| Score 2 : Baseline (n=196) | 1.5 (0.3 to 4.4) |
| Score 2 : Month 6 (n=151) | 1.3 (0.2 to 4.7) |
| Score 3 : Baseline (n=196) | 1.5 (0.3 to 4.4) |
| Score 3 : Month 6 (n=151) | 1.3 (0.2 to 4.7) |
| Score 4 : Baseline (n=196) | 1.5 (0.3 to 4.4) |
| Score 4 : Month 6 (n=151) | 0.7 (0 to 3.6) |
| Score 5 : Baseline (n=196) | 0.5 (0 to 2.8) |
| Score 5 : Month 6 (n=151) | 0.7 (0 to 3.6) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera: Score 1: Baseline (n=101) | 98.0 |
| Mircera: Score 2: Baseline (n=101) | 2.0 |
| Mircera: Score 3: Baseline (n=101) | 0 |
| Mircera: Score 4: Baseline (n=101) | 0 |
| Mircera: Score 5: Baseline (n=101) | 0 |
| Recormon: Score 1: Baseline (n=34) | 94.1 |
| Recormon: Score 2: Baseline (n=34) | 0 |
| Recormon: Score 3: Baseline (n=34) | 0 |
| Recormon: Score 4: Baseline (n=34) | 2.9 |
| Recormon: Score 5: Baseline (n=34) | 2.9 |
| Eprex: Score 1: Baseline (n=21) | 90.5 |
| Eprex: Score 2: Baseline (n=21) | 0 |
| Eprex: Score 3: Baseline (n=21) | 9.5 |
| Eprex: Score 4: Baseline (n=21) | 0 |
| Eprex: Score 5: Baseline (n=21) | 0 |
| Aranesp: Score 1: Baseline (n=40) | 90.0 |
| Aranesp: Score 2: Baseline (n=40) | 2.5 |
| Aranesp: Score 3: Baseline (n=40) | 2.5 |
| Aranesp: Score 4: Baseline (n=40) | 5.0 |
| Aranesp: Score 5: Baseline (n=40) | 0 |
| Mircera: Score 1: Month 6 (n=66) | 100.0 |
| Mircera: Score 2: Month 6 (n=66) | 0 |
| Mircera: Score 3: Month 6 (n=66) | 0 |
| Mircera: Score 4: Month 6 (n=66) | 0 |
| Mircera: Score 5: Month 6 (n=66) | 0 |
| Recormon: Score 1: Month 6 (n=29) | 96.6 |
| Recormon: Score 2: Month 6 (n=29) | 0 |
| Recormon: Score 3: Month 6 (n=29) | 3.4 |
| Recormon: Score 4: Month 6 (n=29) | 0 |
| Recormon: Score 5: Month 6 (n=29) | 0 |
| Eprex: Score 1: Month 6 (n=19) | 94.7 |
| Eprex: Score 2: Month 6 (n=19) | 5.3 |
| Eprex: Score 3: Month 6 (n=19) | 0 |
| Eprex: Score 4: Month 6 (n=19) | 0 |
| Eprex: Score 5: Month 6 (n=19) | 0 |
| Aranesp: Score 1: Month 6 (n=37) | 89.2 |
| Aranesp: Score 2: Month 6 (n=37) | 2.7 |
| Aranesp: Score 3: Month 6 (n=37) | 2.7 |
| Aranesp: Score 4: Month 6 (n=37) | 2.7 |
| Aranesp: Score 5: Month 6 (n=37) | 2.7 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Once a month: Baseline (n=196) | 63.8 (56.6 to 70.5) |
| Once a month: Month 6 (n=151) | 49.0 (40.8 to 57.3) |
| Twice a month: Baseline (n=196) | 17.3 (12.3 to 23.4) |
| Twice a month: Month 6 (n=151) | 23.8 (17.3 to 31.4) |
| Once a week: Baseline (n=196) | 12.8 (8.4 to 18.3) |
| Once a week: Month 6 (n=151) | 17.2 (11.6 to 24.2) |
| Twice a week: Baseline (n=196) | 2.0 (0.6 to 5.1) |
| Twice a week: Month 6 (n=151) | 2.0 (0.4 to 5.7) |
| Three times a week: Baseline (n=196) | 1.0 (0.1 to 3.6) |
| Three times a week: Month 6 (n=151) | 0.7 (0 to 3.6) |
| Other: Baseline (n=196) | 3.1 (1.1 to 6.5) |
| Other: Month 6 (n=151) | 7.3 (3.7 to 12.7) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera: Once a month: Baseline (n=101) | 83.2 |
| Mircera: Once a month: Month 6 (n=66) | 75.8 |
| Mircera: Twice a month: Baseline (n=101) | 14.9 |
| Mircera: Twice a month: Month 6 (n=66) | 15.2 |
| Mircera: Once a week: Baseline (n=101) | 1.0 |
| Mircera: Once a week: Month 6 (n=66) | 3.0 |
| Mircera: Twice a week: Baseline (n=101) | 1.0 |
| Mircera: Twice a week: Month 6 (n=66) | 0 |
| Mircera: Three times a week: Baseline (n=101) | 0 |
| Mircera: Three times a week: Month 6 (n=66) | 0 |
| Mircera: Other: Baseline (n=101) | 0 |
| Mircera: Other: Month 6 (n=66) | 6.1 |
| Recormon: Once a month: Baseline (n=34) | 44.1 |
| Recormon: Once a month: Month 6 (n=29) | 27.6 |
| Recormon: Twice a month: Baseline (n=34) | 14.7 |
| Recormon: Twice a month: Month 6 (n=29) | 31.0 |
| Recormon: Once a week: Baseline (n=34) | 35.3 |
| Recormon: Once a week: Month 6 (n=29) | 31.0 |
| Recormon: Twice a week: Baseline (n=34) | 2.9 |
| Recormon: Twice a week: Month 6 (n=29) | 6.9 |
| Recormon: Three times a week: Baseline (n=34) | 0 |
| Recormon: Three times a week: Month 6 (n=29) | 3.4 |
| Recormon: Other: Baseline (n=34) | 2.9 |
| Recormon: Other: Month 6 (n=29) | 0 |
| Eprex: Once a month: Baseline (n=21) | 33.3 |
| Eprex: Once a month: Month 6 (n=19) | 10.5 |
| Eprex: Twice a month: Baseline (n=21) | 0 |
| Eprex: Twice a month: Month 6 (n=19) | 15.8 |
| Eprex: Once a week: Baseline (n=21) | 42.9 |
| Eprex: Once a week: Month 6 (n=19) | 52.6 |
| Eprex: Twice a week: Baseline (n=21) | 9.5 |
| Eprex: Twice a week: Month 6 (n=19) | 5.3 |
| Eprex: Three times a week: Baseline (n=21) | 4.8 |
| Eprex: Three times a week: Month 6 (n=19) | 0 |
| Eprex: Other: Baseline (n=21) | 9.5 |
| Eprex: Other: Month 6 (n=19) | 15.8 |
| Aranesp: Once a month: Baseline (n=40) | 47.5 |
| Aranesp: Once a month: Month 6 (n=37) | 37.8 |
| Aranesp: Twice a month: Baseline (n=40) | 35.0 |
| Aranesp: Twice a month: Month 6 (n=37) | 37.8 |
| Aranesp: Once a week: Baseline (n=40) | 7.5 |
| Aranesp: Once a week: Month 6 (n=37) | 13.5 |
| Aranesp: Twice a week: Baseline (n=40) | 0 |
| Aranesp: Twice a week: Month 6 (n=37) | 0 |
| Aranesp: Three times a week: Baseline (n=40) | 2.5 |
| Aranesp: Three times a week: Month 6 (n=37) | 0 |
| Aranesp: Other: Baseline (n=40) | 7.5 |
| Aranesp: Other: Month 6 (n=37) | 10.8 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Preferred O/M: Baseline ESA T/W: Baseline (n=5) | 80.0 |
| Preferred O/M: Baseline ESA T/W: Month 6 (n=2) | 50.0 |
| Preferred O/M: Baseline ESA B/W: Baseline (n=14) | 28.6 |
| Preferred O/M: Baseline ESA B/W: Month 6 (n=6) | 0 |
| Preferred O/M: Baseline ESA O/W: Baseline (n=29) | 27.6 |
| Preferred O/M: Baseline ESA O/W: Month 6 (n=24) | 12.5 |
| Preferred O/M: Baseline ESA Q2W: Baseline (n=51) | 49.0 |
| Preferred O/M: Baseline ESA Q2W: Month 6 (n=38) | 13.2 |
| Preferred O/M: Baseline ESA Q4W: Baseline (n=75) | 98.7 |
| Preferred O/M: Baseline ESA Q4W: Month 6 (n=59) | 96.6 |
| Preferred O/M: Baseline ESA other: Baseline (n=21) | 47.6 |
| Preferred O/M: Baseline ESA other: Month 6 (n=22) | 36.4 |
| Preferred B/M: Baseline ESA T/W: Baseline (n=5) | 0 |
| Preferred B/M: Baseline ESA T/W: Month 6 (n=2) | 0 |
| Preferred B/M: Baseline ESA B/W: Baseline (n=14) | 28.6 |
| Preferred B/M: Baseline ESA B/W: Month 6 (n=6) | 33.3 |
| Preferred B/M: Baseline ESA O/W: Baseline (n=29) | 10.3 |
| Preferred B/M: Baseline ESA O/W: Month 6 (n=24) | 8.3 |
| Preferred B/M: Baseline ESA Q2W: Baseline (n=51) | 47.1 |
| Preferred B/M: Baseline ESA Q2W: Month 6 (n=38) | 81.6 |
| Preferred B/M: Baseline ESA Q4W: Baseline (n=75) | 0 |
| Preferred B/M: Baseline ESA Q4W: Month 6 (n=59) | 0 |
| Preferred B/M: Baseline ESA other: Baseline (n=21) | 9.5 |
| Preferred B/M: Baseline ESA other: Month 6 (n=22) | 4.5 |
| Preferred O/W: Baseline ESA T/W: Baseline (n=5) | 0 |
| Preferred O/W: Baseline ESA T/W: Month 6 (n=2) | 50.0 |
| Preferred O/W: Baseline ESA B/W: Baseline (n=14) | 28.6 |
| Preferred O/W: Baseline ESA B/W: Month 6 (n=6) | 33.3 |
| Preferred O/W: Baseline ESA O/W: Baseline (n=29) | 62.1 |
| Preferred O/W: Baseline ESA O/W: Month 6 (n=24) | 79.2 |
| Preferred O/W: Baseline ESA Q2W: Baseline (n=51) | 2.0 |
| Preferred O/W: Baseline ESA Q2W: Month 6 (n=38) | 2.6 |
| Preferred O/W: Baseline ESA Q4W: Baseline (n=75) | 0 |
| Preferred O/W: Baseline ESA Q4W: Month 6 (n=59) | 1.7 |
| Preferred O/W: Baseline ESA other: Baseline (n=21) | 9.5 |
| Preferred O/W: Baseline ESA other: Month 6 (n=22) | 9.1 |
| Preferred B/W: Baseline ESA T/W: Baseline (n=5) | 0 |
| Preferred B/W: Baseline ESA T/W: Month 6 (n=2) | 0 |
| Preferred B/W: Baseline ESA B/W: Baseline (n=14) | 14.3 |
| Preferred B/W: Baseline ESA B/W: Month 6 (n=6) | 33.3 |
| Preferred B/W: Baseline ESA O/W: Baseline (n=29) | 0 |
| Preferred B/W: Baseline ESA O/W: Month 6 (n=24) | 0 |
| Preferred B/W: Baseline ESA Q2W: Baseline (n=51) | 2.0 |
| Preferred B/W: Baseline ESA Q2W: Month 6 (n=38) | 2.6 |
| Preferred B/W: Baseline ESA Q4W: Baseline (n=75) | 0 |
| Preferred B/W: Baseline ESA Q4W: Month 6 (n=59) | 0 |
| Preferred B/W: ESA other: Baseline (n=21) | 4.8 |
| Preferred B/W: ESA other: Month 6 (n=22) | 0 |
| Preferred T/W: Baseline ESA T/W: Baseline (n=5) | 20.0 |
| Preferred T/W: Baseline ESA T/W: Month 6 (n=2) | 0 |
| Preferred T/W: Baseline ESA B/W: Baseline (n=14) | 0 |
| Preferred T/W: Baseline ESA B/W: Month 6 (n=6) | 0 |
| Preferred T/W: Baseline ESA O/W: Baseline (n=29) | 0 |
| Preferred T/W: Baseline ESA O/W: Month 6 (n=24) | 0 |
| Preferred T/W: Baseline ESA Q2W: Baseline (n=51) | 0 |
| Preferred T/W: Baseline ESA Q2W: Month 6 (n=38) | 0 |
| Preferred T/W: Baseline ESA Q4W: Baseline (n=75) | 1.3 |
| Preferred T/W: Baseline ESA Q4W: Month 6 (n=59) | 1.7 |
| Preferred T/W: Baseline ESA other: Baseline (n=21) | 0 |
| Preferred T/W: Baseline ESA other: Month 6 (n=22) | 0 |
| Preferred Other: Baseline ESA T/W: Baseline (n=5) | 0 |
| Preferred Other: Baseline ESA T/W: Month 6 (n=2) | 0 |
| Preferred Other: Baseline ESA B/W: Baseline (n=14) | 0 |
| Preferred Other: Baseline ESA B/W: Month 6 (n=6) | 0 |
| Preferred Other: Baseline ESA O/W: Month 6 (n=29) | 0 |
| Preferred Other: Baseline ESA O/W: Month 6 (n=24) | 0 |
| Preferred Other: Baseline ESA Q2W: Baseline (n=51) | 0 |
| Preferred Other: Baseline ESA Q2W: Month 6 (n=38) | 0 |
| Preferred Other: Baseline ESA Q4W: Baseline (n=75) | 0 |
| Preferred Other: Baseline ESA Q4W: Month 6 (n=59) | 0 |
| Preferred Other:Baseline ESA other:Baseline (n=21) | 28.6 |
| Preferred Other:Baseline ESA other: Month 6 (n=22) | 50.0 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Score 1: Baseline (n=196) | 96.4 (92.8 to 98.6) |
| Score 1: Month 6 (n=151) | 97.4 (93.4 to 99.3) |
| Score 2: Baseline (n=196) | 1.0 (0.1 to 3.6) |
| Score 2: Month 6 (n=151) | 0.7 (0 to 3.6) |
| Score 3: Baseline (n=196) | 0 (0 to 0) |
| Score 3: Month 6 (n=151) | 1.3 (0.2 to 4.7) |
| Score 4: Baseline (n=196) | 0.5 (0 to 2.8) |
| Score 4: Month 6 (n=151) | 0 (0 to 0) |
| Score 5: Baseline (n=196) | 2.0 (0.6 to 5.1) |
| Score 5: Month 6 (n=151) | 0.7 (0 to 3.6) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera: Score 1: Baseline (n=101) | 97.0 |
| Mircera: Score 2: Baseline (n=101) | 1.0 |
| Mircera: Score 4: Baseline (n=101) | 0 |
| Mircera: Score 5: Baseline (n=101) | 2.0 |
| Mircera: Score 1: Month 6 (n=66) | 100.0 |
| Mircera: Score 2: Month 6 (n=66) | 0 |
| Mircera: Score 3: Month 6 (n=66) | 0 |
| Mircera: Score 5: Month 6 (n=66) | 0 |
| Recormon: Score 1: Baseline (n=34) | 100.0 |
| Recormon: Score 2: Baseline (n=34 | 0 |
| Recormon: Score 4: Baseline (n=34 | 0 |
| Recormon: Score 5: Baseline (n=34 | 0 |
| Recormon: Score 1: Month 6 (n=29) | 96.6 |
| Recormon: Score 2: Month 6 (n=29) | 3.4 |
| Recormon: Score 3: Month 6 (n=29) | 0 |
| Recormon: Score 5: Month 6 (n=29) | 0 |
| Eprex: Score 1: Baseline (n=21) | 100.0 |
| Eprex: Score 2: Baseline (n=21) | 0 |
| Eprex: Score 4: Baseline (n=21) | 0 |
| Eprex: Score 5: Baseline (n=21) | 0 |
| Eprex: Score 1: Month 6 (n=19) | 94.7 |
| Eprex: Score 2: Month 6 (n=19) | 0 |
| Eprex: Score 3: Month 6 (n=19) | 0 |
| Eprex: Score 5: Month 6 (n=19) | 5.3 |
| Aranesp: Score 1: Baseline (n=40) | 90.0 |
| Aranesp: Score 2: Baseline (n=40) | 2.5 |
| Aranesp: Score 4: Baseline (n=40) | 2.5 |
| Aranesp: Score 5: Baseline (n=40) | 5.0 |
| Aranesp: Score 1: Month 6 (n=37) | 94.6 |
| Aranesp: Score 2: Month 6 (n=37) | 0 |
| Aranesp: Score 3: Month 6 (n=37) | 5.4 |
| Aranesp: Score 5: Month 6 (n=37) | 0 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Score 1: Baseline (n=196) | 2.0 (0.6 to 5.1) |
| Score 3: Baseline (n=196) | 2.6 (0.8 to 5.9) |
| Score 4: Baseline (n=196) | 6.6 (3.6 to 11.1) |
| Score 5: Baseline (n=196) | 88.8 (83.5 to 92.8) |
| Score 1: Month 6 (n=151) | 0.7 (0 to 3.6) |
| Score 3: Month 6 (n=151) | 2.0 (0.4 to 5.7) |
| Score 4: Month 6 (n=151) | 4.0 (1.5 to 8.4) |
| Score 5: Month 6 (n=151) | 93.4 (88.2 to 96.8) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera: Score 1: Baseline (n=101) | 4.0 |
| Mircera: Score 3: Baseline (n=101) | 1.0 |
| Mircera: Score 4: Baseline (n=101) | 5.0 |
| Mircera: Score 5: Baseline (n=101) | 90.1 |
| Mircera: Score 1: Month 6 (n=66) | 0 |
| Mircera: Score 3: Month 6 (n=66) | 0 |
| Mircera: Score 4: Month 6 (n=66) | 1.5 |
| Mircera: Score 5: Month 6 (n=66) | 98.5 |
| Recormon: Score 1: Baseline (n=34) | 0 |
| Recormon: Score 3: Baseline (n=34) | 2.9 |
| Recormon: Score 4: Baseline (n=34) | 11.8 |
| Recormon: Score 5: Baseline (n=34) | 85.3 |
| Recormon: Score 1: Month 6 (n=29) | 0 |
| Recormon: Score 3: Month 6 (n=29) | 3.4 |
| Recormon: Score 4: Month 6 (n=29) | 6.9 |
| Recormon: Score 5: Month 6 (n=29) | 89.7 |
| Eprex: Score 1: Baseline (n=21) | 0 |
| Eprex: Score 3: Baseline (n=21) | 0 |
| Eprex: Score 4: Baseline (n=21) | 0 |
| Eprex: Score 5: Baseline (n=21) | 100.0 |
| Eprex: Score 1: Month 6 (n=19) | 5.3 |
| Eprex: Score 3: Month 6 (n=19) | 5.3 |
| Eprex: Score 4: Month 6 (n=19) | 0 |
| Eprex: Score 5: Month 6 (n=19) | 89.5 |
| Aranesp: Score 1: Baseline (n=40) | 0 |
| Aranesp: Score 3: Baseline (n=40) | 7.5 |
| Aranesp: Score 4: Baseline (n=40) | 10.0 |
| Aranesp: Score 5: Baseline (n=40) | 82.5 |
| Aranesp: Score 1: Month 6 (n=37) | 0 |
| Aranesp: Score 3: Month 6 (n=37) | 2.7 |
| Aranesp: Score 4: Month 6 (n=37) | 8.1 |
| Aranesp: Score 5: Month 6 (n=37) | 89.2 |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Score 1: Baseline (n=196) | 88.8 (83.5 to 92.8) |
| Score 1: Month 6 (n=151) | 92.1 (86.5 to 95.8) |
| Score 2: Baseline (n=196) | 8.2 (4.7 to 12.9) |
| Score 2: Month 6 (n=151) | 6.0 (2.8 to 11.0) |
| Score 3: Baseline (n=196) | 1.5 (0.3 to 4.4) |
| Score 3: Month 6 (n=151) | 1.3 (0.2 to 4.7) |
| Score 4: Baseline (n=196) | 0.5 (0 to 2.8) |
| Score 4: Month 6 (n=151) | 0.7 (0 to 3.6) |
| Score 5: Baseline (n=196) | 1.0 (0.1 to 3.6) |
| Score 5: Month 6 (n=151) | 0 (0 to 0) |
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported.
| percentage of participants | Chronic Renal Anemia Participants |
|---|---|
| Mircera: Score 1: Baseline (n=101) | 92.1 |
| Mircera: Score 2: Baseline (n=101) | 6.9 |
| Mircera: Score 3: Baseline (n=101) | 1.0 |
| Mircera: Score 4: Baseline (n=101) | 0 |
| Mircera: Score 5: Baseline (n=101) | 0 |
| Mircera: Score 1: Month 6 (n=66) | 97.0 |
| Mircera: Score 2: Month 6 (n=66) | 3.0 |
| Mircera: Score 3: Month 6 (n=66) | 0 |
| Mircera: Score 4: Month 6 (n=66) | 0 |
| Recormon: Score 1: Baseline (n=34) | 91.2 |
| Recormon: Score 2: Baseline (n=34 | 5.9 |
| Recormon: Score 3: Baseline (n=34) | 2.9 |
| Recormon: Score 4: Baseline (n=34) | 0 |
| Recormon: Score 5: Baseline (n=34) | 0 |
| Recormon: Score 1: Month 6 (n=29) | 96.6 |
| Recormon: Score 2: Month 6 (n=29) | 3.4 |
| Recormon: Score 3: Month 6 (n=29) | 0 |
| Recormon: Score 4: Month 6 (n=29) | 0 |
| Eprex: Score 1: Baseline (n=21) | 71.4 |
| Eprex: Score 2: Baseline (n=21) | 23.8 |
| Eprex: Score 3: Baseline (n=21) | 4.8 |
| Eprex: Score 4: Baseline (n=21) | 0 |
| Eprex: Score 5: Baseline (n=21) | 0 |
| Eprex: Score 1: Month 6 (n=19) | 84.2 |
| Eprex: Score 2: Month 6 (n=19) | 15.8 |
| Eprex: Score 3: Month 6 (n=19) | 0 |
| Eprex: Score 4: Month 6 (n=19) | 0 |
| Aranesp: Score 1: Baseline (n=40) | 87.5 |
| Aranesp: Score 2: Baseline (n=40) | 5.0 |
| Aranesp: Score 3: Baseline (n=40) | 0 |
| Aranesp: Score 4: Baseline (n=40) | 2.5 |
| Aranesp: Score 5: Baseline (n=40) | 5.0 |
| Aranesp: Score 1: Month 6 (n=37) | 83.8 |
| Aranesp: Score 2: Month 6 (n=37) | 8.1 |
| Aranesp: Score 3: Month 6 (n=37) | 5.4 |
| Aranesp: Score 4: Month 6 (n=37) | 2.7 |
Collected over From Baseline up to Month 6. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chronic Renal Anemia Participants | — | 3/196 (1.5%) | — |
| Event | Chronic Renal Anemia Participants |
|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/196 |
| Cardiac failure congestiveCardiac disorders | 1/196 |
| Chronic kidney diseaseRenal and urinary disorders | 1/196 |
| DeathGeneral disorders | 1/196 |
All enrolled participants
| Age, Continuous(years) | Chronic Renal Anemia Participants |
|---|---|
| Mean | 74.6 ± 10.6 |
| Sex: Female, Male(Participants) | Chronic Renal Anemia Participants |
|---|---|
| Female | 85 |
| Male | 111 |
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche